Newly Diagnosed

Treatment

Ameloblastoma

Nasopharynx Only

ENT0043
A Pilot Study of Dabrafenib for Patients with BRAF-Mutated Ameloblastoma
PI: Colevas
Stanford

ENT0025
Phase II Sequential and Concurrent Chemoradiation for Advanced Nasopharyngeal Carcinoma (NPC)
PI: Colevas
Stanford

NRGHN001
Phase II/III Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Deoxyribonucleic Acid
PI: Le
NRG

RTOG1008
Phase II Adj Concurrent XRT + Chemo vs XRT Alone in Resected High-Risk Malignant Salivary Gland Tumors
PI: Le
RTOG

Salivary Gland

Resection Unfavorable

ENT0057
A Phase III Cisplatin-based Chemoradiotherapy +/- Nivolumab (Anti-PD-1) in H&N Squamous Cell Carcinoma
PI: Le
NRG

ENT0045
Phase II Neoadjuvant & Adjuvant Tx IRX-2 Regimen in Newly Dx Stage II / III / IVA SCC of the Oral Cavity
PI: Kaplan
IRX Therapeutics

Oropharynx, Oral Cavity, Larynx, Hypopharynx

Resection Unfavorable

ENT0057
A Phase III Cisplatin-based Chemoradiotherapy +/- Nivolumab (Anti-PD-1) in H&N Squamous Cell Carcinoma
PI: Le
RTOG

ENT0045
Phase II Neoadjuvant & Adjuvant Tx IRX-2 Regimen in Newly Dx Stage II / III / IVA SCC of the Oral Cavity
PI: Kaplan
IRX Therapeutics

Oropharynx Only

ENT0061
Pilot PD-1 Inhibition in Squamous Cell Carcinoma of the Head and Neck (SCCHN)
PI: Colevas
Stanford

Oropharynx Only

ENT0060
Phase II da Vinci SP Surgical System Investigation in TORS Procedures for Malignant Tumor Resection
PI: Holsinger
Pending

Oral Cavity Only

ENT0061
Pilot PD-1 Inhibition in Squamous Cell Carcinoma of the Head and Neck (SCCHN)
PI: Colevas
Stanford

P16+/P16-

Resection Favorable

ENT0057
A Phase III Cisplatin-based Chemoradiotherapy +/- Nivolumab (Anti-PD-1) in H&N Squamous Cell Carcinoma
PI: Le
RTOG

ECOG3311
Phase II Surgery + Low/Std Dose IMRT in Resectable p16+
Locally Advanced Oropharynx CA
PI: Holsinger
ECOG

P16+

Oropharynx Only

P16+

Resection Favorable

KEY

Pending
Open for Enrollment
Observational Study
Optional Path
Extension Study
Immunotherapy
Enrollment on Hold